COVID-19: Wockhardt in discussions with vaccine developers to offer drug substance

By: |
Updated: Dec 01, 2020 2:30 PM

Drug firm Wockhardt on Tuesday said it is in discussions with a number of global COVID-19 vaccine developers to offer drug substance as well as fill and finish manufacturing facilities to them.

Vaccination centres will either be hospitals or facilities linked to hospitals.

Drug firm Wockhardt on Tuesday said it is in discussions with a number of global COVID-19 vaccine developers to offer drug substance as well as fill and finish manufacturing facilities to them.

According to the company, the UK government has reserved one fill and finish production line at Wockhardt UK for its exclusive use for 18 months in order to guarantee the supply of vaccines required to fight against COVID-19.

“We are in discussions with a number of vaccine developers worldwide offering both drug substance, and fill and finish manufacturing, because most of the companies want drug substance as well as formulation product,” Wockhardt Chairman Habil Khorakiwala said during a virtual media conference.

Wockhardt is offering such options as a contract manufacturing organisation activity or as distribution rights, depending on what they want, he added.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1China records dozens new coronavirus cases, defends response
2Bird flue: Over 1,200 bird deaths reported in Delhi since January 6, say officials
3Nasal COVID-19 vaccine will be easy to give to children: AIIMS director Randeep Guleria